Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NRBO

NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRBO
DateTimeSourceHeadlineSymbolCompany
04/17/20248:05AMPR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/01/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/28/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/13/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/04/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/04/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/29/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/29/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/14/20248:52AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/12/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/01/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/01/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/18/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/18/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/09/20248:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/09/20248:30AMPR Newswire (US)NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price RequirementNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/02/20248:01AMPR Newswire (US)NeuroBo to Participate in Industry and Investor Conferences in JanuaryNASDAQ:NRBONeuroBo Pharmaceuticals Inc
12/28/20239:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
12/28/20238:45AMPR Newswire (US)NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
12/19/20239:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
12/19/20238:43AMPR Newswire (US)NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:NRBONeuroBo Pharmaceuticals Inc
12/07/20239:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
12/01/20238:31AMPR Newswire (US)NeuroBo to Participate in Investor Conferences in DecemberNASDAQ:NRBONeuroBo Pharmaceuticals Inc
11/13/20234:29PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
11/13/20234:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
11/13/20234:05PMPR Newswire (US)NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
11/06/20238:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
11/06/20238:05AMPR Newswire (US)NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.NASDAQ:NRBONeuroBo Pharmaceuticals Inc
10/30/20238:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
10/17/20238:01AMPR Newswire (US)NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NRBO